Companies › Blue Earth Diagnostics
3 active drug programs in 3 registered trials: 1 Phase 2, 1 Phase 1, 1 Phase 4; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| fluciclovine (18F) 18F-labeled amino acid analog for PET imaging of prostate cancer | – | Phase 4 | Prostate Cancer | Dec 2027 |
| [68Ga]BED003 Fibroblast activation protein (FAP) targeting PET imaging agent | FAP | Phase 2 | Colorectal Cancer | Feb 2028 |
| [18F]FPyQCP Fibroblast activation protein (FAP) inhibitor positron emission tomography tracer | FAP | Phase 1 | Colorectal Cancer | Jan 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07569926 | fluciclovine (18F) | Phase 4 | Prostate Cancer | Oncology | Dec 2027 |
| NCT07432633 | [18F]FPyQCP | Phase 1 | Colorectal Cancer | Oncology | Jan 2028 |
| NCT07702292 | [68Ga]BED003 | Phase 2 | Colorectal Cancer | Oncology | Feb 2028 |
Chengdu New Radiomedicine Technology SOFIE Lantheus Medical Imaging Advenchen Laboratories OSE Immunotherapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.